MARKET

CNCR

CNCR

Loncar Cancer Immunotherapy ETF
NASDAQ

Real-time Quotes | Provided by Morningstar

26.19
0.00
0.02%
Closed 16:00 08/07 EDT
OPEN
26.20
PREV CLOSE
26.18
HIGH
26.50
LOW
26.04
VOLUME
5.08K
TURNOVER
--
52 WEEK HIGH
28.55
52 WEEK LOW
12.00
TOTAL ASSET
39.84M
YTD YIELD
11.71%
1D
5D
1M
3M
1Y
5Y

CNCR News

More
Biotechnology Innovation During COVID-19
Seeking Alpha - Article · 06/11 07:47
ACADIA: The Company's Perspectives In Numbers.
Seeking Alpha - Article · 05/15 15:18
USO, UCO, LABU and ITB among weekly ETF movers
Seeking Alpha - Article · 05/01 21:13
USO, OIL, TQQQ and SQQQ among weekly ETF movers
Seeking Alpha - Article · 04/18 03:51
Will These Tech Stock Valuations Last?
Seeking Alpha - Article · 02/13 13:06
Should Investors Avoid U.S. Healthcare Stocks In An Election Year?
Seeking Alpha - Article · 02/10 14:35
Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
Seeking Alpha - Article · 11/22/2019 18:34
VXX, UNG, UGAZ and TVIX among weekly ETF movers
Seeking Alpha - Article · 11/01/2019 20:54

Profile

Fund Name
Loncar Cancer Immunotherapy ETF
Risk
High Risk
Inception Date
2015-10-13
Benchmark
Loncar Cancer Immunotherapy TR USD*100.0%
Advisor Company
Loncar Investments
Custodian
U.S. Bank N.A
Manager
Denise Krisko, Austin Wen, Rafael Zayas

Asset Allocation

43.50M
  • 99.9531%
  • 0.00%
  • 0.0469%
  • 0.00%

2020 Q2

43.50M

2020 Q1

30.88M

2019 Q4

39.92M

2019 Q2

38.09M

2019 Q1

38.87M

Dividend History

Ex-Div Date
Dividend Per Share
12/28/2017
0.3502
12/29/2015
0.1055